Whitney Ijem
Stock Analyst at Canaccord Genuity
(2.03)
# 2,830
Out of 4,784 analysts
96
Total ratings
34.15%
Success rate
-4.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $385 → $390 | $268.46 | +45.27% | 8 | Mar 21, 2025 | |
| RGLS Regulus Therapeutics | Maintains: Buy | $28 | $1.73 | +1,518.50% | 5 | Mar 17, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $9 | $0.43 | +2,003.79% | 2 | Mar 17, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $18 → $6 | $0.64 | +834.00% | 6 | Mar 13, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $74 → $68 | $11.58 | +487.22% | 5 | Mar 10, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $39 → $36 | $7.59 | +374.31% | 6 | Mar 3, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $80 → $81 | $54.80 | +47.81% | 6 | Feb 27, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $39 | $28.10 | +38.79% | 2 | Feb 26, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $121 → $136 | $37.82 | +259.60% | 8 | Feb 18, 2025 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Hold | $408 → $424 | $492.69 | -13.94% | 8 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 | $8.07 | +1,015.24% | 5 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.93 | +314.51% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 | $0.38 | +3,312.07% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $70.41 | +113.04% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $32 | $5.22 | +513.03% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $71.44 | +17.58% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $111.79 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $4.16 | +5,669.23% | 4 | Jul 23, 2019 |
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $385 → $390
Current: $268.46
Upside: +45.27%
Regulus Therapeutics
Mar 17, 2025
Maintains: Buy
Price Target: $28
Current: $1.73
Upside: +1,518.50%
Generation Bio Co.
Mar 17, 2025
Maintains: Buy
Price Target: $9
Current: $0.43
Upside: +2,003.79%
Tenaya Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $0.64
Upside: +834.00%
Arcturus Therapeutics Holdings
Mar 10, 2025
Maintains: Buy
Price Target: $74 → $68
Current: $11.58
Upside: +487.22%
Rocket Pharmaceuticals
Mar 3, 2025
Maintains: Buy
Price Target: $39 → $36
Current: $7.59
Upside: +374.31%
Rhythm Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $80 → $81
Current: $54.80
Upside: +47.81%
Palvella Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $39
Current: $28.10
Upside: +38.79%
Ultragenyx Pharmaceutical
Feb 18, 2025
Maintains: Buy
Price Target: $121 → $136
Current: $37.82
Upside: +259.60%
Vertex Pharmaceuticals
Feb 12, 2025
Upgrades: Hold
Price Target: $408 → $424
Current: $492.69
Upside: -13.94%
Nov 19, 2024
Maintains: Buy
Price Target: $90
Current: $8.07
Upside: +1,015.24%
Nov 15, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.93
Upside: +314.51%
Nov 14, 2024
Maintains: Buy
Price Target: $13
Current: $0.38
Upside: +3,312.07%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $70.41
Upside: +113.04%
Nov 6, 2024
Maintains: Buy
Price Target: $29 → $32
Current: $5.22
Upside: +513.03%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $71.44
Upside: +17.58%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $111.79
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $4.16
Upside: +5,669.23%